BD Partners with University of Pennsylvania to Enhance Immune Profiling and Therapy Development
- BD partners with the University of Pennsylvania to enhance immune profiling and therapy development through advanced technology.
- The BD FACSDiscover™ A8 Cell Analyzer will be crucial in a 1,000-patient immune profiling study starting in 2026.
- This collaboration exemplifies BD's commitment to innovation in immunotherapy and advancing patient care through research and development.
BD Partners with University of Pennsylvania to Advance Immune Profiling Research
Becton, Dickinson and Company (BD) has embarked on a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, focusing on deep human immune profiling and immune-mediated therapy development. This partnership seeks to enhance understanding of the immune system by creating a high-parameter flow cytometry panel that can analyze over 30 cellular characteristics, including critical phosphorylation markers. The initiative aims to provide insights into cellular responses related to drugs and various disease states, thereby contributing to the development of more effective immunotherapies.
At the heart of this collaboration is the BD FACSDiscover™ A8 Cell Analyzer, a state-of-the-art instrument that will play a key role in a planned 1,000-patient immune profiling study. Slated to begin in the summer of 2026 in collaboration with the Penn Colton Center for Autoimmunity, this study represents a significant step toward leveraging advanced technology to decode the complexities of the immune system. BD will oversee the technical execution using its instrumentation, reagents, software, and informatics, while the scientific and clinical aspects will be directed by I3H. Dr. E. John Wherry of I3H underscores the ambition of this initiative, which seeks to unlock the potential of the human immune system to expedite the development of precise medical treatments.
The collaboration between BD and I3H exemplifies the powerful synergy between academic research and industrial expertise in driving innovation in immunotherapy. By combining cutting-edge technology with rigorous scientific inquiry, the partners aim to produce impactful findings that will be documented in a peer-reviewed manuscript. The anticipated results from this collaboration not only promise to advance the understanding of immune responses but also to enhance therapeutic strategies in treating autoimmune diseases and other health conditions. This project showcases BD's commitment to pioneering advancements in immunotherapy, leveraging the latest in flow cytometry technology to transform immune profiling.
In addition to this partnership, BD continues to focus on developing innovative solutions that address pressing health challenges. By collaborating with leading academic institutions, BD reinforces its role as a key player in the biopharmaceutical industry, dedicated to enhancing patient care through research and development. The company's efforts in advancing immunotherapy highlight the importance of cross-disciplinary approaches in tackling complex medical issues, paving the way for future breakthroughs in healthcare.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

